A U.S. cannabis company has made a bid to acquire Aurora Cannabis Inc., a company based in Edmonton. Aurora has announced the formation of a special committee to review this unsolicited offer from Curaleaf Holdings Inc. If successful, this acquisition would result in the formation of a combined cannabis enterprise operating in 17 countries across Europe, North America, and other global markets.
Curaleaf, a company headquartered in Stamford, Conn., disclosed its intention to acquire all shares of Aurora after private negotiations with Aurora’s leadership failed. Despite sending formal letters of intent on June 23 and July 7, Curaleaf stated that Aurora’s board declined to engage in meaningful discussions regarding the proposal.
Curaleaf has proposed a payment of $4 US per share to Aurora shareholders, along with an additional $0.75 US in cash for each Aurora share. However, Aurora claims that the financial terms were only outlined in the July 7 letter and not in the initial correspondence.
Aurora refuted Curaleaf’s assertion that it rejected the offer without discussion. The Canadian company stated that its lead independent director had ongoing correspondence with Curaleaf’s CEO as late as July 24, expressing the company’s focus on its current business strategy.
Aurora will establish a special committee of independent directors to evaluate the offer and determine its impact on stakeholders. The company emphasized that there is no guarantee of reaching an agreement and that business operations will continue as usual in the interim.
While acknowledging Curaleaf’s interest, analysts cautioned that the proposed offer undervalues Aurora’s long-term potential. They highlighted Aurora’s market leadership in medical cannabis, robust product portfolio, financial strength, and ability to navigate international regulatory challenges as factors that could create substantial value over time.
Curaleaf believes that merging with Aurora would create synergies and enhance shareholder value. The combined revenue of the two companies exceeded $1.5 billion US in the past year, with Curaleaf anticipating annual cost synergies of at least $40 million US post-acquisition.
Curaleaf’s CEO expressed optimism about the merger, emphasizing the benefits of combining global distribution capabilities with Aurora’s international medical cannabis expertise and production capacity. The proposed acquisition aims to provide Aurora shareholders with a diversified global platform and exposure to favorable U.S. regulatory trends.
